Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives

Pia Burman, Lydia Lamb, Ann McCormack

Research output: Contribution to journalReview articlepeer-review

Abstract

The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established however a large number of patients do not respond to treatment and recurrence after cessation of TMZ is common. A number of challenges remain for clinicians such as appropriate patient selection, treatment duration and the role of combination therapy. This review will examine the use of TMZ to treat APT including mechanism of action, treatment regimen and duration; biomarkers predicting response to treatment and patient selection; and current evidence for administration of TMZ in combination with other agents.

Original languageEnglish
Pages (from-to)263-276
Number of pages14
JournalReviews in Endocrine and Metabolic Disorders
Volume21
Issue number2
DOIs
Publication statusPublished - 2020 Mar 9

Subject classification (UKÄ)

  • Urology and Nephrology

Free keywords

  • Aggressive pituitary tumour
  • Biomarker
  • Combination therapy
  • Pituitary carcinoma
  • Temozolomide

Fingerprint

Dive into the research topics of 'Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives'. Together they form a unique fingerprint.

Cite this